Fiche publication
Date publication
avril 2024
Journal
Nature communications
Auteurs
Membres identifiés du Cancéropôle Est :
Dr METZGER Daniel
,
Dr LAVERNY Gilles
,
Dr CHARVET Céline
,
Dr BILLAS Isabelle
,
Dr COTTARD Félicie
Tous les auteurs :
Cai Q, Sahu R, Ueberschlag-Pitiot V, Souali-Crespo S, Charvet C, Silem I, Cottard F, Ye T, Taleb F, Metzger E, Schuele R, Billas IML, Laverny G, Metzger D, Duteil D
Lien Pubmed
Résumé
Synthetic glucocorticoids (GC), such as dexamethasone, are extensively used to treat chronic inflammation and autoimmune disorders. However, long-term treatments are limited by various side effects, including muscle atrophy. GC activities are mediated by the glucocorticoid receptor (GR), that regulates target gene expression in various tissues in association with cell-specific co-regulators. Here we show that GR and the lysine-specific demethylase 1 (LSD1) interact in myofibers of male mice, and that LSD1 connects GR-bound enhancers with NRF1-associated promoters to stimulate target gene expression. In addition, we unravel that LSD1 demethylase activity is required for triggering starvation- and dexamethasone-induced skeletal muscle proteolysis in collaboration with GR. Importantly, inhibition of LSD1 circumvents muscle wasting induced by pharmacological levels of dexamethasone, without affecting their anti-inflammatory activities. Thus, our findings provide mechanistic insights into the muscle-specific GC activities, and highlight the therapeutic potential of targeting GR co-regulators to limit corticotherapy-induced side effects.
Mots clés
Animals, Male, Histone Demethylases, metabolism, Glucocorticoids, pharmacology, Dexamethasone, pharmacology, Receptors, Glucocorticoid, metabolism, Mice, Muscular Atrophy, chemically induced, Muscle, Skeletal, metabolism, Mice, Inbred C57BL, Gene Expression Regulation, drug effects
Référence
Nat Commun. 2024 04 26;15(1):3563
